| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/18/2023 | 11.8% | Citigroup | $2.1 → $1.8 | Maintains | Buy |
| 08/07/2023 | 210.56% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/04/2023 | 24.22% | Chardan Capital | → $2 | Reiterates | Neutral → Neutral |
| 05/17/2023 | 179.5% | Cantor Fitzgerald | $5 → $4.5 | Maintains | Overweight |
| 05/17/2023 | 272.67% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 05/17/2023 | 210.56% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 03/30/2023 | 272.67% | JMP Securities | → $6 | Reiterates | → Market Outperform |
| 03/30/2023 | 210.56% | HC Wainwright & Co. | $1.5 → $5 | Maintains | Buy |
| 12/23/2022 | 210.56% | Raymond James | $2 → $5 | Maintains | Outperform |
| 12/22/2022 | 210.56% | Cantor Fitzgerald | $0.8 → $5 | Upgrades | Neutral → Overweight |
| 08/15/2022 | -6.83% | HC Wainwright & Co. | $2 → $1.5 | Maintains | Buy |
| 08/12/2022 | — | Chardan Capital | Downgrades | Buy → Neutral | |
| 08/12/2022 | 24.22% | Raymond James | → $2 | Upgrades | Market Perform → Outperform |
| 05/09/2022 | 24.22% | HC Wainwright & Co. | $4 → $2 | Maintains | Buy |
| 05/06/2022 | 24.22% | Chardan Capital | $2.5 → $2 | Maintains | Buy |
| 04/14/2022 | 55.28% | Chardan Capital | $8 → $2.5 | Maintains | Buy |
| 04/14/2022 | 210.56% | JMP Securities | $8 → $5 | Maintains | Market Outperform |
| 02/14/2022 | 396.89% | Chardan Capital | $18 → $8 | Maintains | Buy |
| 02/14/2022 | 396.89% | JMP Securities | $29 → $8 | Maintains | Market Outperform |
| 02/14/2022 | 148.45% | HC Wainwright & Co. | $20 → $4 | Maintains | Buy |
| 02/14/2022 | — | Raymond James | Downgrades | Strong Buy → Market Perform | |
| 02/01/2022 | 1080.12% | Raymond James | → $19 | Initiates Coverage On | → Strong Buy |
| 08/09/2021 | 1018.01% | Chardan Capital | $20 → $18 | Maintains | Buy |
| 05/03/2021 | 1142.24% | Stifel | → $20 | Initiates Coverage On | → Buy |
| 08/11/2020 | 1142.24% | Chardan Capital | $25 → $20 | Maintains | Buy |
| 11/19/2019 | 1949.69% | Citigroup | $40 → $33 | Maintains | Buy |
| 11/14/2018 | 2384.47% | Cantor Fitzgerald | → $40 | Initiates Coverage On | → Overweight |
| 09/19/2018 | 2073.91% | Evercore ISI Group | → $35 | Initiates Coverage On | → Outperform |
What is the target price for ProQR Therapeutics (PRQR)?
The latest price target for ProQR Therapeutics (NASDAQ: PRQR) was reported by Citigroup on September 18, 2023. The analyst firm set a price target for $1.80 expecting PRQR to rise to within 12 months (a possible 11.80% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ProQR Therapeutics (PRQR)?
The latest analyst rating for ProQR Therapeutics (NASDAQ: PRQR) was provided by Citigroup, and ProQR Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for ProQR Therapeutics (PRQR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProQR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProQR Therapeutics was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.
Is the Analyst Rating ProQR Therapeutics (PRQR) correct?
While ratings are subjective and will change, the latest ProQR Therapeutics (PRQR) rating was a maintained with a price target of $2.10 to $1.80. The current price ProQR Therapeutics (PRQR) is trading at is $1.61, which is out of the analyst's predicted range.